American Heart Association – 2020

Baris Gencer – Efficacy of Lowering Low-Density Lipoprotein Cholesterol in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Daniel Marcusa – Relationship Between Baseline LDL-C and %LDL-C Reduction with Evolocumab in the FOURIER Trial

Kazuma Oyama – Reduction with Evolocumab in Complex Coronary Revascularization: Insights from the FOURIER Trial

Parth Patel – A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease

Anthony Carnicelli – In-Hospital vs Out-of-Hospital Cardiac Arrest in Patients Presenting to Cardiac Intensive Care Units From the Critical Care Cardiology Trials Network (CCCTN)

David Berg – A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients with T2DM in DECLARE-TIMI 58

David Berg – Biomarker-Based Heart Failure Risk Stratification in Patients with Atherosclerotic Cardiovascular Disease: Observations From HPS3/TIMI-55 REVEAL

David Berg – Development of A Novel Biomarker-Based Risk Score for Heart Failure in Patients with Diabetes

Kazuma Oyama – Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients with T2DM in the DECLARE-TIMI 58 Trial

Nicholas Marston – Cardiovascular Outcomes in Patients with Established Atherosclerosis and LDLR Loss of Function: Results from the FOURIER Trial

Nicholas Marston – Combining High-Sensitivity Troponin with the AHAACC Cholesterol Guidelines To Guide Evolocumab Therapy

Remo Furtado – Effects of Evolocumab in Patients with Prior Percutaneous Coronary Intervention: An Analysis from the FOURIER Trial

Thomas Zelniker – Relationship between cardiac biomarkers and major adverse cardiovascular events in DECLARE-TIMI 58

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close